論文（英文）

Shinozaki T, Hagiwara Y, Matsuyama Y. Re. Biases in randomized trials: a conversation between trialists and epidemiologists (Letter). Epidemiology. 2017; 28(4): e40-e41.
Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open. 2017;2:e000151.
Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. Cancer Chemother Pharmacol. 2017;79:813-823.
Ikeda T, Uchida K, Yamauchi Y, Nagase T, Oba K, Yamada Y. Relationship between pre-anesthetic and intra-anesthetic airway resistance in patients undergoing general anesthesia: A prospective observational study. PLoS One 2017;12(2):e0172421.
Nakamura M, Aoyama T, Ishibashi K, Tsuji A, Takinishi Y, Shindo Y, Sakamoto J, Oba K, Mishima H. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study). Cancer Chemother Pharmacol 2017;79:29-36.
Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C, Fujieda S, Nakata K, Murotani K, Oba K, Sakamoto J, Mishima H. Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemother Pharmacol 2016;78:1253-1261.
Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, Atsumi T, Manda N, Kurihara Y, Aoki S; SAIS Study Group. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PLoS One. 2016 Oct 6;11:e0164255.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Ann Surg Oncol. 2016 Sep 8.
Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M; Liver Cancer Study Group of Japan. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol. 2017;52(10):1112-21.
Saitoh A, Saitoh A, Sato I, Shinozaki T, Kamiya H, Nagata S. Effect of stepwise perinatal immunization education: a cluster-randomized controlled trial. Vaccine. 2017;35(12):1645-51.
Jinnouchi H, Kuramitsu S, Shinozaki T, Tomoi Y, Hiromasa T, Kobayashi Y, Domei T, Soga Y, Hyodo M, Shirai S, Ando K. Difference of tissue characteristics between early and late restenosis after second-generation drug-eluting stents implantation: an optical coherence tomography study. Circ J. 2017;81(4):450-7.
Kozuma K, Kashiwabara K, Shinozaki T, Kozuma K, Oba K, Matsuyama Y. Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA). Int J Cardiovasc Imaging. 2017;33(6):779-787. doi: 10.1007/s10554-017-1068-4.
Taniguchi Y, Kitamura A, Murayama H, Amano H, Shinozaki T, Yokota I, Seino S, Nofuji Y, Nishi M, Yokoyama Y, Matsuyama Y, Fujuwara Y, Shinkai S. Mini-Mental State Examination Score Trajectories and Incident Disabling Dementia Among Community-Dwelling Older Japanese. Geriatr Gerontol Int. 2017;17(11):1928-35.
Taniguchi Y, Fujiwara Y, Murayama H, Yokota I, Matsuo E, Seino S , Nofuji Y, Nishi M, Matsuyama Y, Shinkai S. Prospective Study of Trajectories of Physical Performance and Mortality Among Community-Dwelling Older Japanese. J Gerontol A Biol Sci Med Sci. 2016; 71:1492-1499.
Tabuchi T, Goto A, Ito Y, Fukui K, Miyashiro I, Shinozaki T. Smoking at the time of diagnosis and mortality in cancer patients: What benefit does the quitter gain? Int J Cancer. 2017;140(8):1789-95.
Taniguchi Y, Kitamura A, Seino S, Murayama H, Amano H, Nofuji Y, Nishi M, Yokoyama Y, Shinozaki T, Yokota I, Matsuyama Y, Fujiwara Y, Shinkai S. Gait Performance Trajectories and Incident Disabling Dementia Among Community-Dwelling Older Japanese. J Am Med Dir Assoc. 2017;18(2):192.e13-192.e20.
Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Watanabe T, Makuuchi M, Kokudo N. Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: A randomized controlled trial. PLoS One. 2016; 11(9): e0162400.
Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016; 46(5): 372-90.
Moriya J, Matsuyama Y. Estimating treatment effect of high hemoglobin using the principal stratification approach. Jpn J Biometrics. 2016; 37: 7-22.
Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N; Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016; 65(5): 938-943.
Yoshida M, Matsuyama Y. Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry. J Biopharm Stat. 2016; 26(5): 842-58.
Kitahara H, Waseda K, Sakamoto K, Yamada R, Huang CC, Nakatani D, Sakata K, Kawarada O, Yock PG, Matsuyama Y, Yokoi H, Nakamura M, Muramatsu T, Nanto S, Fitzgerald PJ, Honda Y. Impact of attenuated-signal plaque observed by intravascular ultrasound on vessel response after drug-eluting stent implantation. Atherosclerosis. 2017; 259: 68-74.
Zhu Y, Chen CY, Matsuyama Y, Ohashi Y, Franklin JM, Setoguchi S. Comparative validity of methods to select appropriate cutoff weight for probabilistic linkage without unique personal identifiers. Pharmacoepidemiol Drug Saf. 2016; 25(4): 444-52.
Takahashi M, Hasegawa K, Oba M, Saiura A, Arita J, Sakamoto Y, Shinozaki E, Mizunuma N, Matsuyama Y, Kokudo N. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases. Invest New Drugs. 2016; 34(4): 468-73.
Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. Liver Cancer. 2016; 5(3): 175-189.
Iijima R, Nakamura M, Matsuyama Y, Muramatsu T, Yokoi H, Hara H, Okada H, Ochiai M, Suwa S, Hozawa H, Kawai K, Awata M, Mukawa H, Fujita H, Nanto S; J-DESsERT. Effect of optimal medical therapy before procedures on outcomes in coronary patients treated with drug-eluting stents. Am J Cardiol. 2016; 118(6): 790-6.
Kokudo T, Hasegawa K, Amikura K, Uldry E, Shirata C, Yamaguchi T, Arita J, Kaneko J, Akamatsu N, Sakamoto Y, Takahashi A, Sakamoto H, Makuuchi M, Matsuyama Y, Demartines N, Malagó M, Kokudo N, Halkic N. Assessment of preoperative liver function in patients with hepatocellular carcinoma - The albumin-indocyanine green evaluation (ALICE) grade. PLoS One. 2016; 11(7): e0159530.
Ichida A, Hasegawa K, Takayama T, Kudo H, Sakamoto Y, Yamazaki S, Midorikawa Y, Higaki T, Matsuyama Y, Kokudo N. Randomized clinical trial comparing two vessel-sealing devices with crush clamping during liver transection. Br J Surg. 2016; 103(13): 1795-1803.
Takao T, Suka M, Yanagisawa H, Matsuyama Y, Iwamoto Y. Predictive ability of visit-to-visit variability in HbA1c and systolic blood pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes. Diabetes Res Clin Pract. 2017; 128: 15-23.
Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016; 5(3): 190-7.
Hara F, Takashima T, Tsurutani J, Saito T, Taira N, Kashiwabara K, Aihara T, Mukai H. Randomized, optimal dose finding, phase II study of tri-weekly nabpaclitaxel in patients with metastatic breast cancer (ABROAD). Journal of Clinical Trials 2016; 6(3): Article 267. Doi:10.4172/2167-0870.1000267.
Niikura N, Ota Y, Hayashi N, Naito M, Kashiwabara K, Watanabe K, Yamashita T, Mukai H, Umeda M. Evaluation of oral care to prevent oral mucositis in estrogen receptor-positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): randomized controlled phase III trial. Japanese Journal of Clinical Oncology 2016: 46(9): 879–882. Doi: 10.1093/jjco/hyw077.
Takeuchi F, Komaki H, Nakamura H, Yonemoto N, Kashiwabara K, Kimura E, Takeda S. Trends in steroid therapy for Duchenne muscular dystrophy in Japan. Muscle & Nerve 2016; 54(4): 673–680. Doi: 10.1002/mus.25083.
Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T. Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-associated Colorectal Cancer. Gastroenterology. 2016 Aug 11. [Epub ahead of print].
Furihata T, Kinugawa S, Fukushima A, Takada S, Homma T, Masaki Y, Abe T, Yokota T, Oba K, Okita K, Tsutsui H. Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure. Int J Cardiol 2016 ;220:483-7.
Hazama S, Maeda H, Iwamoto S, Kim HM, Takemoto H, Kobayashi K, Sakamoto J, Nagata N, Oba K, Mishima H. A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study). Clin Colorectal Cancer. 2016 Jul 18. [Epub ahead of print]
Matsui T, Nagata N, Hirata K, Okazaki S, Sato S, Nakamura M, Kim H, Oba K, Sakamoto J, Mishima H. Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial. Anticancer Res 2016;36:3437-43.
Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S. A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32). J Cancer Res Ther. 2018 Sep;14(Supplement):S761-S766.
Mabe K, Kato M, Oba K, Nakagawa S, Seki H, Katsuki S, Yamashita K, Ono S, Shimizu Y, Sakamoto N; Sapporo Consensus Study Group. A prospective, multicenter survey on the validity of shorter periendoscopic cessation of antithrombotic agents in Japan. J Gastroenterol. 2016 Apr 16. [Epub ahead of print]
Noguchi K, Sakakibara M, Asakawa N, Tokuda Y, Kamiya K, Yoshitani T, Oba K, Miyauchi K, Nishizaki Y, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y, Kimura K, Origasa H, Isshiki T, Morino Y, Daida H, Tsutsui H; PACIFIC investigators. Higher Hemoglobin A1c After Discharge Is an Independent Predictor of Adverse Outcomes in Patients With Acute Coronary Syndrome　- Findings From the PACIFIC Registry. Circ J 2016;80:1607-14.
Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res. 2017;26:445-453.
Tani Y, Kondo N, Nagamine Y, Shinozaki T, Kondo K, Kawachi I, Fujiwara T. Childhood socioeconomic disadvantage is associated with lower mortality in older Japanese men: the JAGES cohort study. Int J Epidemiol. 2016;45(4):1226-1235.
Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M, Yamamoto M, Shinozaki T, Miyazaki T, Miyauchi K, Nagao K, Hirayama A, Yoshimura M, Komuro I, Nagai R, Daida H. Association between the docosahexaenoic acid to arachidonic acid ratio and acute coronary syndrome: a multicenter observational study. BMC Cardiovasc Disord. 2016;16(1):143.
Lee SL, Daimon M, Di Tullio MR, Homma S, Nakao T, Kawata T, Kimura K, Shinozaki T, Hirokawa M, Kato T, Mizuno Y, Watanabe M, Yatomi Y, Yamazaki T, Komuro I. Relationship of left ventricular diastolic function to obesity and overweight in a Japanese population with preserved left ventricular ejection fraction. Circ J. 2016;80(9):1951-6.
Ishiguro C, Takeuchi Y, Uyama Y, Tawaragi T. The MIHARI Project: Establishing a new framework for pharmacoepidemiological drug safety assessments by the Pharmaceuticals and Medical Devices Agency of Japan. Pharmacoepidemiol Drug Saf. 2016; 25(7): 854–859.
Takano A, Miyamoto Y, Kawakami N, Matsumoto T, Shinozaki T, Sugimoto T. Web-based cognitive behavioral relapse prevention program with tailored feedback for people with methamphetamine and other drug use problems: protocol for a multicenter randomized controlled trial in Japan. BMC Psychiatry. 2016;16:87.
Matsumoto M, Kato M, Oba K, Abiko S, Tsuda M, Miyamoto S, Mizushima T, Ono M, Omori S, Takahashi M, Ono S, Mabe K, Nakagawa M, Nakagawa S, Kudo T, Shimizu Y, Sakamoto N. Multicenter randomized controlled study to assess the effect of prophylactic clipping on post-polypectomy delayed bleeding. Dig Endosc. 2016 Mar 28. doi: 10.1111/den.12661.
Kishikawa J, Kazama S, Oba K, Hasegawa K, Anzai H, Harada Y, Abe H, Matsusaka K, Hongo K, Oba M, Yasuda K, Otani K, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Hata K, Kawai K, Nozawa H, Yamaguchi H, Ishihara S, Sunami E, Ushiku T, Kitayama J, Fukayama M, Kokudo N, Watanabe T. CD133 Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer with Synchronous Liver Metastasis. Ann Surg Oncol. 2016 Jan 29. [Epub ahead of print]
Takeuchi Y, Bonkobara M. Receptor tyrosine kinase KIT: Prognostic and therapeutic involvement in canine mast cell tumours. Vet J. 2016; 210: 5–6.

TOP